Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

Fig. 6

In vivo amplified anti-tumor effect of UCMS@Pep-aPDL1. A Schematics of the program used for spine metastasis tumor mode and IDO-based peptide tumor vaccine-mediated synergetic cancer treatment. Time-dependent (B) body weight and (C) tumor volume of mice in different groups. D Tumor progression in different groups evaluated by IVIS. E Tumor specimens extracted after the mice had been sacrificed. F H&E-stained histological images, G TUNEL-stained pathological changes and Ki-67-stained cellular proliferation in tumor tissues (scale bars = 100 μm). (*P < 0.05, **P < 0.01, ***P < 0.001, n > 3)

Back to article page